Sarah Weiss, MD

Sarah Weiss, MD, discussed key IGNYTE trial findings of RP1 and nivolumab in patients with advanced melanoma who progressed on prior anti-PD-1 therapy.

The results of the CHAARTED trial, which looked at whether the addition of upfront chemotherapy to hormonal therapy improved overall survival in patients with hormone-sensitive metastatic prostate cancer, were presented at the ASCO Annual Meeting.

Multiple abstracts on melanoma and skin cancer were reviewed at the ASCO Annual Meeting, with a focus on new treatment approaches in non-melanoma skin cancers, particularly basal cell carcinoma and Merkel cell carcinoma.

When treating patients, we often ask ourselves how the results of the tests we order will potentially change our management of the patient, or change the way we think about our patient’s disease, or offer information that will enhance our treatment approach.